Stock will rise with either event. I bet Michael French would prefer to stay independent and bring the stock all the way back to 2009 levels and higher. Would qualify as one of the most dramatic turnarounds in RNAi industry history years from now. Sounds crazy, but RNAi stocks in late 2012
may be the greatest biotech investment opportunity of the next 20 years.